Phase II study of high dose cytarabine combined with a single high dose of idarubicin for newly diagnosed patients with AML [acute myeloid leukemia]: the AML-3 Protocol

Trial Profile

Phase II study of high dose cytarabine combined with a single high dose of idarubicin for newly diagnosed patients with AML [acute myeloid leukemia]: the AML-3 Protocol

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs Cytarabine (Primary) ; Idarubicin (Primary) ; Etoposide; Granulocyte colony-stimulating factors; Lintuzumab
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Dec 2009 Actual end date (Mar 2003) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 May 2009 Exclusion criteria amended from NCT
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top